# An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

> **NCT02552940** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 140 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02552940
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-31
- **Primary completion:** 2017-10-23
- **Final completion:** 2017-10-23
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2018-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02552940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02552940, "An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02552940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*